The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
Neil Howard Segal
Research Funding - Bristol-Myers Squibb
F. Stephen Hodi
No relevant relationships to disclose
Rachel E. Sanborn
Consultant or Advisory Role - Bristol-Myers Squibb
Thomas Gajewski
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Walter John Urba
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Bernard A. Fox
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Suzanne Louise Topalian
Consultant or Advisory Role - Bristol-Myers Squibb (U); Jounce Therapeutics; Sanofi
Research Funding - Bristol-Myers Squibb
Other Remuneration - Amplimmune; Bristol-Myers Squibb
Drew M. Pardoll
Consultant or Advisory Role - Aduro Biotech (U); Amplimmune (U); ImmuneXcite
Georgia Kollia
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Dan McDonald
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Su Young Kim
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
William Howard Sharfman
No relevant relationships to disclose